BRIEF published on 04/03/2024 at 14:05, 1 year 8 months ago Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder Regulatory Pathway
BRIEF published on 04/03/2024 at 14:05, 1 year 8 months ago Clairvoyant Therapeutics fait progresser l'essai clinique sur la psilocybine pour les troubles liés à la consommation d'alcool Essai Clinique Thérapeutique Clairvoyante Traitement À La Psilocybine Trouble Lié À La Consommation D'alcool Voie Réglementaire
PRESS RELEASE published on 04/03/2024 at 14:00, 1 year 8 months ago Psilocybin Clinical Trial Sponsored by Clairvoyant Therapeutics Reaches 90% Randomization Clairvoyant Therapeutics aims to commercialize psilocybin treatment for alcohol use disorder by 2025. Company's trial progressing well, expecting results in 2024 & financing round underway Commercialization Clinical Trial Clairvoyant Therapeutics Psilocybin Treatment Alcohol Use Disorder
PRESS RELEASE published on 11/29/2023 at 13:00, 2 years ago Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder
PRESS RELEASE published on 03/20/2023 at 12:00, 2 years 8 months ago First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
Published on 12/05/2025 at 02:35, 4 hours 51 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 6 hours 26 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 21 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 26 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 07:00, 25 minutes ago Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 55 minutes ago CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 35 minutes ago EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 11 hours ago Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 11 hours 11 minutes ago Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 18:14, 13 hours 11 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 13 hours 26 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 13 hours 41 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
